# A Phase IIb Study of AZD5462 in Patients With Chronic Heart Failure

> **NCT06299826** · PHASE2 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 375 (actual)

## Conditions studied

- Chronic Heart Failure

## Interventions

- **DRUG:** AZD5462
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06299826
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-06-04
- **Primary completion:** 2026-02-10
- **Final completion:** 2026-02-10
- **Target enrollment:** 375 (ACTUAL)
- **Last updated:** 2026-02-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06299826

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06299826, "A Phase IIb Study of AZD5462 in Patients With Chronic Heart Failure". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT06299826. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*